How Broadening the Analysis of Compound Factors Allows for Predictive Solubility Solutions - White Paper
Product Development
Author: Marshall Crew, Ph.D.
Monday, June 06, 2016

The Biopharmaceutics Classification System (BCS), developed by the U.S. Food and Drug Administration to simplify and accelerate the drug development process, helps companies when they file for bioequivalence of dosage forms based on in vitro dissolution testing.The objective of the BCS system is to predict in vivo performance of drugs from in vitro measurements of solubility and permeability. The system has evolved to classify low-soluble drugs according to their permeability (BCS Class II or IV). A compound’s classification (I through IV) is indicative of its potential bioavailability.


Please complete the short form below to download this whitepaper.

Looking for Solutions?

We can help.